News

Embody Advances Biologic Augmentation Market with First-Of-Its-Kind Collagen Implant

Embody, Inc., a privately-held medical device company developing novel collagen-based technologies for soft tissue injury and repair, announced today the expansion and clinical use cases of TAPESTRY® Biointegrative Implant in the U.S. market. TAPESTRY Biointegrative Implant is the first collagen-based implant with a bioengineered micro-architecture and biostimulative, highly organized type I collagen chemistry specifically designed for the management and protection of tendon injuries. The unique combination of the collagen chemistry and structural integrity provides unparalleled clinical utility and sizing across a broad range of tendon applications including, but not limited to, foot and ankle, knee, and shoulder procedures.

“Catastrophic failure and clinical dysfunction associated with poor subscapularis tendon healing rates following shoulder arthroplasty leads to suboptimal functional outcomes and costly re-operations for our patients,” said Amit Nathani, MD, an Orthopaedic Surgeon and Shoulder Specialist in Santa Barbara, California. “TAPESTRY combines the benefits of collagen-based chemistry with unique sizing, hydrophilicity, and handling characteristics appropriate to augment total shoulder procedures, offering the potential to enhance healing and reduce soft tissue failures.”

“There is a strong clinical need for a better solution to treat tendon injury of the foot & ankle,” said Alan Ng, DPM, FACFAS, at Advanced Orthopedic & Sports Medicine Specialists in Denver, CO. “The TAPESTRY implant is unlike anything else I have used in its ability to form new, dense collagenous tissue at the site of the implantation combined with its superior handling and sizing make it ideal for a variety of challenging tendon procedures including Achilles and paroneal tendons.”

“Following the initial surgical procedures with TAPESTRY, we are seeing continued use and expanded interest across a wide range of demanding tendon applications including subscapularis, patellar, peroneal and Achilles tendons where formative products have lacked the combination of handling, structural integrity, and a biostimulative chemistry,” said Jeff Conroy, CEO of Embody. “We continue to expand our range of sizes and shapes to rapidly accommodate every surgeon’s need.”

Recent News

05/20/2024

Governor Youngkin Announces New VIPC-Led Initiative that Catalyzes and Attracts Investment into Virginia-based, Innovation-driven Startups and Entrepreneurs

Governor Glenn Youngkin announced a new initiative led by Virginia Innovation Partnership Corporation (VIPC) that expands investment and growth opportunities for Virginia-based, innovation-driven startups and entrepreneurial ecosystems throughout the Commonwealth. Leveraging previous Virginia-awarded federal funding from the U.S. Department of Treasury, under its SSBCI Equity/Venture Capital Program, VIPC’s Virginia Invests launches new investment partnerships with an

05/12/2024

Nanochon closes $4M Series Seed Prime

Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round. The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others. Nanochon intends to use the funds to

05/09/2024

Agrospheres Announces Major Commercial Development Agreement with FMC Corporation

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and crop health, today announced the signing of a major collaboration with FMC Corporation (NYSE:FMC), a global leader in agriculture sciences. The long-term alliance represents a major milestone in launching AgroSpheres’ vertically integrated product pipeline. Powered by a recent $25M Series B funding round and construction